Consumer Health Neurology

MLB Receives FDA Approval for TML-6 IND Application to Treat Alzheimer's Disease

MLB (Merry Life Biomedical Company, Ltd., Taiwan )  a biomedical company, announced that  the U.S. Food and Drug Administration (FDA) h...

 June 07, 2024 | News

Luye Pharma and Towa Pharmaceutical File NDA in Japan for Rivastigmine Twice Weekly Patch for Alzheimer’s

Luye Pharma Group announced that its partner Towa Pharmaceutical Co., Ltd. (Towa) has filed a New Drug Application (NDA) to the Ministry of Health, Labour ...

 June 07, 2024 | News

NeuShen Therapeutics Begins Phase I Trial of NS-136, a Potential Breakthrough in Schizophrenia Treatment

NeuShen Therapeutics , a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today a...

 May 10, 2024 | News

Eisai Launches Injectable Fycompa in Japan for Epilepsy Treatment

Eisai Co., Ltd. announcedthat the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (I...

 April 19, 2024 | News

Actinogen Medical Launches Phase 2b XanaMIA Trial for Alzheimer's, Marks First Patient Treatment

Actinogen Medical Limited (ASX: ACW) announces that the first patient has been randomized and treated in the XanaMIA phase 2b clin...

 April 16, 2024 | News

Teva Validates AJOVY® Efficacy and Safety in China Phase 3 Migraine Trial

AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significanc...

 April 15, 2024 | News

NTT Research Foundation Establishes Pioneering Fellowship Program at Harvard to Explore the Physics of Intelligence

NTT Research Foundation funds Fellowship Program in new field of Physics of Intelligence. Field of study bridges computer science, brain science and phy...

 April 12, 2024 | News

Eisai and Biogen Seek FDA Approval for Monthly Alzheimer's Treatment Dosing

Eisai Co., Ltd. and Biogen Inc. have taken a significant step forward in the fight against Alzheimer’s disease by submitting a Supplemental Biologics...

 April 01, 2024 | News

AriBio Secures Exclusive $770M Deal for Alzheimer's Drug in China

AriBio Co., Ltd. (AriBio), announces signing of exclusive marketing rights for AR1001, an investigational drug for early Alzheimer’s disease, in Chin...

 March 25, 2024 | News

NeuExcell Therapeutics Launches Pioneering Gene Therapy Trial for Glioblastoma Patients

NeuExcell Therapeutics, a leading biotechnology company focused on in vivo neural regenerative therapies, announces the successful dosing of the ...

 March 22, 2024 | News

Cellectricon launches new Neuroinflammation Research Service

Cellectricon, a services provider dedicated to advancing neuroscience drug discovery, has launched the Neuroinflammation Research Service module. Establish...

 March 13, 2024 | News

Ono Pharmaceutical Forms Strategic Alliance with Harvard University for Drug Discovery

 Ono Pharmaceutical announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University&nbs...

 March 12, 2024 | News

Sunbird Bio Advances Alzheimer's Diagnosis with APEX Blood Test, Matching PET Scan Accuracy

Sunbird Bio, a biotechnology company developing proprietary protein- and blood-based technologies to improve diagnosis and treatment of neurological disord...

 March 06, 2024 | News

Elevating Alzheimer's Detection: Aptamer Group's CSO Dr. David Bunka Discusses the Impact of Optimer Binders

  In a compelling conversation with BioPharma APAC, Dr. David Bunka, the Chief Scientific Officer (CSO) of Aptamer Group, unveils an ambitious endeav...

 March 01, 2024 | Interview

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in